Real-life experience with inotersen in hereditary transthyretin amyloidosis with late-onset phenotype: Data from an early-access program in Italy.
ATTRv
amyloidosis
inotersen
real life
Journal
European journal of neurology
ISSN: 1468-1331
Titre abrégé: Eur J Neurol
Pays: England
ID NLM: 9506311
Informations de publication
Date de publication:
07 2022
07 2022
Historique:
revised:
02
03
2022
received:
07
02
2022
accepted:
09
03
2022
pubmed:
16
3
2022
medline:
15
6
2022
entrez:
15
3
2022
Statut:
ppublish
Résumé
Hereditary transthyretin (TTR) amyloidosis (ATTRv) is a dominantly inherited, adult-onset, progressive, and fatal disease caused by mutations in the transthyretin gene. Therapeutic agents approved for this disease include the TTR stabilizer tafamidis and the gene-silencing drugs patisiran and inotersen. Inotersen is an antisense oligonucleotide that suppresses the hepatic production of transthyretin. After European Medical Agency approval in 2018, an early-access program was opened in Italy, and in this article, we present the long-term outcome of a cohort of Italian ATTRv patients who received inotersen within this program. This is a multicenter, observational, retrospective study of patients affected by ATTRv that started inotersen during the early-access program. The primary end point was safety. Secondary end points included change from baseline in familial amyloid polyneuropathy (FAP) stage, Polyneuropathy Disability, Neuropathy Impairment Scale, Compound Autonomic Dysfunction Test, Norfolk Quality of Life-Diabetic Neuropathy, troponin, N-terminal pro-brain natriuretic peptide, interventricular septum thickness, and body mass index. In total, 23 patients were enrolled. No patient permanently discontinued the treatment because of thrombocytopenia, and no cases of severe thrombocytopenia were observed. Five patients discontinued the treatment permanently because of voluntary withdrawal (two patients), renal failure after infective pyelonephritis, not related to inotersen, drug-related hypotension, and amyloid-negative crescentic glomerulonephritis. In seven patients, dosing frequency was reduced to every 2 weeks due to recurrent thrombocytopenia. Considering the FAP stage, only two patients worsened, whereas the other 21 patients remained stable until the last follow-up available. The long-term safety profile of inotersen is favorable. Neurologic disease severity at baseline is the main factor associated with progression.
Sections du résumé
BACKGROUND AND PURPOSE
Hereditary transthyretin (TTR) amyloidosis (ATTRv) is a dominantly inherited, adult-onset, progressive, and fatal disease caused by mutations in the transthyretin gene. Therapeutic agents approved for this disease include the TTR stabilizer tafamidis and the gene-silencing drugs patisiran and inotersen. Inotersen is an antisense oligonucleotide that suppresses the hepatic production of transthyretin. After European Medical Agency approval in 2018, an early-access program was opened in Italy, and in this article, we present the long-term outcome of a cohort of Italian ATTRv patients who received inotersen within this program.
METHODS
This is a multicenter, observational, retrospective study of patients affected by ATTRv that started inotersen during the early-access program. The primary end point was safety. Secondary end points included change from baseline in familial amyloid polyneuropathy (FAP) stage, Polyneuropathy Disability, Neuropathy Impairment Scale, Compound Autonomic Dysfunction Test, Norfolk Quality of Life-Diabetic Neuropathy, troponin, N-terminal pro-brain natriuretic peptide, interventricular septum thickness, and body mass index.
RESULTS
In total, 23 patients were enrolled. No patient permanently discontinued the treatment because of thrombocytopenia, and no cases of severe thrombocytopenia were observed. Five patients discontinued the treatment permanently because of voluntary withdrawal (two patients), renal failure after infective pyelonephritis, not related to inotersen, drug-related hypotension, and amyloid-negative crescentic glomerulonephritis. In seven patients, dosing frequency was reduced to every 2 weeks due to recurrent thrombocytopenia. Considering the FAP stage, only two patients worsened, whereas the other 21 patients remained stable until the last follow-up available.
CONCLUSIONS
The long-term safety profile of inotersen is favorable. Neurologic disease severity at baseline is the main factor associated with progression.
Identifiants
pubmed: 35289020
doi: 10.1111/ene.15325
pmc: PMC9314115
doi:
Substances chimiques
Oligonucleotides
0
Prealbumin
0
Inotersen
0IEO0F56LV
Types de publication
Journal Article
Multicenter Study
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2148-2155Informations de copyright
© 2022 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology.
Références
Muscle Nerve. 2019 Aug;60(2):169-175
pubmed: 31093980
Neurol Sci. 2020 Nov 14;:
pubmed: 33188616
BMC Neurol. 2021 Feb 12;21(1):70
pubmed: 33579211
Eur J Neurol. 2022 Jul;29(7):2148-2155
pubmed: 35289020
J Peripher Nerv Syst. 2021 Jun;26(2):155-159
pubmed: 33960565
N Engl J Med. 2018 Jul 05;379(1):22-31
pubmed: 29972757
Amyloid. 2020 Dec;27(4):259-265
pubmed: 32696671
Ther Clin Risk Manag. 2020 Feb 21;16:109-123
pubmed: 32110029
N Engl J Med. 2018 Jul 5;379(1):11-21
pubmed: 29972753
Brain Sci. 2021 Apr 27;11(5):
pubmed: 33925301
Neurology. 2012 Aug 21;79(8):785-92
pubmed: 22843282
Neurology. 2015 Aug 25;85(8):675-82
pubmed: 26208957
JAMA. 2013 Dec 25;310(24):2658-67
pubmed: 24368466
Brain Sci. 2021 Apr 19;11(4):
pubmed: 33921571
Lancet Neurol. 2011 Dec;10(12):1086-97
pubmed: 22094129
Eur J Neurol. 2020 Aug;27(8):1374-1381
pubmed: 32343462